The collective findings in the post-MI population do not support dual-agent suppression of Tekturna with other drugs inhibiting the renin-angiotensin system at this time, concluded Dr. Solomon, presenter of ASPIRE trial.
Going forward, what does this mean for Novartis’ attempt to boost sales when blockbuster BP drug Diovan loses market exclusivity? Read More > ….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.